Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Complement factor D (Homo sapiens (Human)) | BDBM355665![]() (1-(2-{(1R,3S,5S)-3-[(1R,2S)-2-(2-Chloro-phenyl)-cy...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 22 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355637![]() ((1R,3S,5R)-2-[2-(3-Acetyl-indazol-1- yl)-acetyl]-2...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 29 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355700![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 30 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355683![]() (1-{2-[(1R,3S,5R)-3-((1R,2R)-2- Fluoro-2-phenyl- cy...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 30 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355654![]() (5-Ethyl-1-{2-oxo-2-[(1R,3S,5R)-3- ((1R,2S)-2-pheny...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 31 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355681![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 32 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355702![]() (1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2- Chloro-phenyl)- ...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 35 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355685![]() (1-(2-{(1R,3S,5R)-3-[2-Fluoro-2-(2- fluoro-phenyl)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 36 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355709![]() (1-(2-{(1R,3S,5R)-3-[2-(2,4- Difluoro-phenyl)- cycl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 36 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355703![]() (1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2- Chloro-phenyl)- ...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 37 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355694![]() ((2S,4R)-1-[2-(3-Acetyl-indazol-1- yl)-acetyl]-4-fl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 37 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355666![]() ((1R,3S,5S)-2-[2-(3-Acetyl-pyrazolo[3,4-c]pyridin-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 37 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355693![]() (1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2-Chloro-phenyl)-cy...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 39 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355645![]() ((2S,3S,4S)-1-[2-(3-Acetyl-indazol-1- yl)-acetyl]-4...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 40 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355701![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 44 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355653![]() (1-{2-[(2S,4R)-4-Fluoro-2-((1R,2S)- 2-phenyl-cyclop...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 44 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355708![]() (1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2- Chloro-phenyl)- ...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 45 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355722![]() (3-Acetyl-1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2-fluoro-p...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 46 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355674![]() (1-{2-[(1R,3S,5R)-3-((1R,2R)-2-fluoro-2-phenyl-cycl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 48 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355647![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)- 2-phenyl-cyclop...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 60 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355661![]() (5-Fluoro-1-{2-[(1R,3S,5R)-3- ((1R,2R)-2-fluoro-2-p...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 60 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355698![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 64 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355644![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)- 2-phenyl-cyclop...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 65 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355679![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 66 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355706![]() (1-(2-{(2S,4R)-4-Fluoro-2-[(1R,2S)- 2-(2-fluoro-phe...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 90 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355640![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 106 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355691![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 109 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355660![]() (5,6-Difluoro-1-{2-[(1R,3S,5R)-3- ((1R,2R)-2-fluoro...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 110 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355669![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 112 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355713![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-(3- phenyl-cyclohexylcarb...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 114 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355650![]() (5-Methyl-1-{2-oxo-2-[(1R,3S,5R)-3- ((1R,2S)-2-phen...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 115 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355652![]() (1-{2-[(2S,4R)-4-Fluoro-2-((1R,2S)- 2-phenyl-cyclop...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 117 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355649![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)- 2-phenyl-cyclop...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 118 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355662![]() (5-Chloro-1-{2-[(1R,3S,5R)-3- ((1R,2R)-2-fluoro-2-p...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 119 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355664![]() ((1R,3S,5S)-2-[2-(3-Acetyl-pyrazolo[3,4-c]pyridin-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 119 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355643![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 123 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355705![]() (1-(2-{(1R,3S,5R)-3-[(1R,2S)-2-(2- Fluoro-phenyl)- ...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 125 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355697![]() ((1R,2S,5S)-3-[2-(3-Acetyl-indazol- 1-yl)-acetyl]-3...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 131 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355675![]() (1-(2-{(2S,4R)-4-Fluoro-2-[(1R,2S)- 2-(2-fluoro-phe...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 142 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355638![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[4,3-c]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 147 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355663![]() ((1R,3S,5S)-2-[2-(3-Acetyl-pyrazolo[3,4-b]pyridin-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 172 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355648![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)- 2-phenyl-cyclop...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 172 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355678![]() (1-{2-[(1R,3S,5R)-3-((1R,2R)-2- Fluoro-2-phenyl- cy...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 214 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355689![]() ((1R,3S,5R)-2-[2-(3-Acetyl-pyrazolo[3,4-b]pyridin-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 225 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355646![]() ((1R,3S,5R)-2-[2-(3-Acetyl-5,6- dimethoxy-indazol-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 226 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355717![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-(3- phenyl-cyclohexylcarb...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 230 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355695![]() ((2S,4R)-1-[2-(3-Acetyl-indazol-1- yl)-acetyl]-4-fl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 294 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355707![]() (1-(2-{(2S,4R)-2-[(1R,2S)-2-(4- Chloro-phenyl)- cyc...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 309 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355667![]() (US9815819, 32) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 326 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355685![]() (1-(2-{(1R,3S,5R)-3-[2-Fluoro-2-(2- fluoro-phenyl)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 367 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355655![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-((1R,2S)- 2-phenyl-cyclop...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 368 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355636![]() ((1R,3S,5R)-2-[2-(3-Acetyl-indazol-1- yl)-acetyl]-2...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 386 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355671![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 466 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355713![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-(3- phenyl-cyclohexylcarb...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 475 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355668![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355673![]() (1-{2-[(1R,3S,5R)-3-((1S,2S)-2-fluoro-2-phenyl-cycl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 635 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355709![]() (1-(2-{(1R,3S,5R)-3-[2-(2,4- Difluoro-phenyl)- cycl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 640 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355720![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-((R)-3- phenyl-cyclopenty...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 648 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355639![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 702 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355704![]() (1-(2-{(1R,3S,5R)-3-[(1S,2R)-2-(2- Chloro-phenyl)- ...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 764 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355696![]() ((1R,2S,5S)-3-[2-(3-Acetyl-indazol- 1-yl)-acetyl]-3...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 776 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355641![]() (5,6-Dimethoxy-1-{2-oxo-2- [(1R,3S,5R)-3-((1R,2S)-2...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 789 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355699![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 791 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355657![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 870 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355670![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 902 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355682![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 991 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355685![]() (1-(2-{(1R,3S,5R)-3-[2-Fluoro-2-(2- fluoro-phenyl)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 992 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355672![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.06E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355684![]() (1-{2-[(1R,3S,5R)-3-((1S,2S)-2- Fluoro-2-phenyl- cy...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.19E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355676![]() (1-(2-{(2S,4R)-4-Fluoro-2-[(1S,2R)- 2-(2-fluoro-phe...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.19E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355720![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-((R)-3- phenyl-cyclopenty...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.23E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355651![]() (1-{2-[(2S,4R)-4-Fluoro-2-((1R,2S)- 2-phenyl-cyclop...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.24E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355718![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-((S)-3- phenyl-cyclopenty...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.29E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355656![]() (1-(2-{(1R,3S,5R)-3-[(1S,2R)-2-(2- Chloro-phenyl)- ...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.40E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355718![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-((S)-3- phenyl-cyclopenty...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.45E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355690![]() ((1R,3S,5R)-2-[2-(3-acetyl-pyrazolo[3,4-b]pyridin-1...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.58E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355692![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.61E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355713![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-(3- phenyl-cyclohexylcarb...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355677![]() (1-{2-[(1R,3S,5R)-3-((1S,2S)-2- Fluoro-2-phenyl- cy...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.65E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355709![]() (1-(2-{(1R,3S,5R)-3-[2-(2,4- Difluoro-phenyl)- cycl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.76E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355685![]() (1-(2-{(1R,3S,5R)-3-[2-Fluoro-2-(2- fluoro-phenyl)-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 3.88E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355642![]() (5,6-Dimethoxy-1-{2-oxo-2- [(1R,3S,5R)-3-((1S,2R)-2...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 4.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355713![]() (1-{2-Oxo-2-[(1R,3S,5R)-3-(3- phenyl-cyclohexylcarb...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 5.65E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355709![]() (1-(2-{(1R,3S,5R)-3-[2-(2,4- Difluoro-phenyl)- cycl...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 7.76E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355680![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-b]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.04E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355658![]() ((1R,3S,5R)-2-[2-(3-Acetyl- pyrazolo[3,4-c]pyridin-...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.32E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Complement factor D (Homo sapiens (Human)) | BDBM355659![]() (1-{2-[(1R,3S,5R)-3-((1S,2R)-1- Methyl-2-phenyl-cyc...) | PDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD GoogleScholar | PC cid PC sid UniChem | US Patent | n/a | n/a | 1.76E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Novartis AG US Patent | Assay Description Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun... | US Patent US9815819 (2017) BindingDB Entry DOI: 10.7270/Q2QF8W1V | |||||||||||
More data for this Ligand-Target Pair |